Next Article in Journal
Stakeholders Perspectives on the Introduction of an Additional Injectable Vaccine Under the Universal Immunization Programme in India
Previous Article in Journal
Comparative Analysis of Health Economic Evaluations for Different Influenza Vaccines and Vaccination Strategies in China: A Systematic Review
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Vaccines
Volume 13
Issue 3
10.3390/vaccines13030333
vaccines-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Pooled Analysis of the Effect of Pre-Existing Ad5 Neutralizing Antibodies on the Immunogenicity of Adenovirus Type 5 Vector-Based COVID-19 Vaccine from Eight Clinical Trials

by
Wenqing Liu
1,†,
Yuqing Li
1,†,
Xiaolong Li
2,
Feiyu Wang
2,
Runjie Qi
1,
Tao Zhu
2,* and
Jingxin Li
1,3,*
1
School of Public Health, National Vaccine Innovation Platform, Nanjing Medical University, Nanjing 211166, China
2
CanSino Biologics Inc., Tianjin 300457, China
3
Jiangsu Provincial Medical Innovation Center, National Health Commission Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, Jiangsu Provincial Academy of Preventive Medicine, Nanjing 210009, China
*
Authors to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Vaccines 2025, 13(3), 333; https://doi.org/10.3390/vaccines13030333
Submission received: 24 February 2025 / Accepted: 19 March 2025 / Published: 20 March 2025
Browse Figure
Review Reports Versions Notes

Abstract

:
Background: Pre-existing adenovirus immunity restricts the utilization of adenovirus-vectored vaccines. The current study aims to conduct a pooled analysis of eight clinical trials to evaluate the influence of pre-existing Ad5 neutralizing antibodies on immunogenicity of Ad5-nCoV. Methods: The primary outcome indicator of this pooled analysis is the geometric mean titers (GMTs) of live SARS-CoV-2 NAbs against the wild-type strain on day 28 post-vaccination. Participants were divided into two cohorts: an adolescent cohort comprising individuals aged 6–17 years and an adult cohort with individuals aged 18 years and older. Within each cohort, individuals were further categorized into three subgroups based on their Ad5-nCoV vaccination schedules: one subgroup received a single intramuscular dose as the primary regimen (Ad5-IM-prime), another received an intramuscular dose as the heterologous prime-boost regimen (Ad5-IM-boost), and the last subgroup received an aerosolized dose as the heterologous prime-boost regimen (Ad5-IH-boost). Results: A total of 3512 participants were included in this pooled analysis. In the Ad5-IM-prime subgroup, there were 1001 adolescents and 1450 adults; in the Ad5-IM-boost subgroup, there were 65 adolescents and 396 adults; and in the Ad5-IH-boost subgroup, there were 207 adolescents and 393 adults. In the adult cohort, the GMTs of NAbs against wild-type SARS-CoV-2 on day 28 post-vaccination for the Ad5-IM-prime, Ad5-IM-boost, and Ad5-IH-boost subgroups were 35.6 (95% CI: 32.0, 39.7), 358.3 (95% CI: 267.6, 479.6), and 2414.1 (95% CI: 2006.9, 2904.0), respectively, with negative (less than 1:12) pre-existing NAb titers compared to 10.7 (95% CI: 9.1, 12.6), 116.9 (95% CI: 84.9, 161.1), and 762.7 (95% CI: 596.2, 975.8), respectively, with high (greater than 1:1000) pre-existing NAb titers. A similar trend was observed in the adolescent cohort, where pre-existing immunity was found to reduce the peak of live SARS-CoV-2 Nabs post-vaccination. Conclusions: Regardless of whether Ad5-nCoV is administered as a primary vaccination regimen or as a heterologous prime-boost strategy, a negative impact on immunogenicity can still be observed in the presence of high pre-existing immunity. However, when primary immunization is achieved with inactivated COVID-19 vaccines, aerosol inhalation can significantly enhance the immunogenicity of Ad5-nCoV compared to intramuscular injections of Ad5-nCoV as a booster.

1. Introduction

Adenoviruses are non-enveloped viruses with a double-stranded DNA genome, comprising 252 capsomers arranged in an icosahedral structure. Among these, 240 are hexons and 12 are penton bases. Each hexon is a homotrimer of hexon proteins, and the epitopes on hexons are standard for diagnosing different serotypes. Each penton base is associated with a fiber protrusion, which has serotype specificity and contains specific antigen binding sites for agglutination of cells in vitro [1]. Adenoviruses themselves have a high immunogenicity and can strongly induce neutralizing responses against the virus’s surface hexon, penton proteins, and fibers after infection.
Adenoviral (Ad) vectors are considered a promising candidate for an ideal vaccine vector due to their fulfilling key criteria related to efficacy, safety, and stability [2]. These vectors are particularly effective at stimulating a robust innate immune response, which is crucial for subsequently promoting elevated levels of both humoral and cellular immune responses. This phenomenon results largely from their ability to preferentially target antigen-presenting cells, which are essential for initiating broad immune reactions [3]. Several recombinant Ad-vectored vaccines have successfully demonstrated their capacity to elicit both humoral and cellular immune responses in various animal models and human clinical trials. Notably, studies conducted in mice [4], non-human primates [5,6], and human participants [7] have yielded encouraging results, highlighting the effectiveness of these vaccines in generating the desired immune responses. Over the past few decades, this innovative vaccine platform has been extensively investigated in both preclinical and clinical settings, leading to the development of vaccines aimed at combating a range of viruses responsible for infectious diseases. Significant examples include vaccines designed to target the Ebola virus [8,9], the Zika virus [10], and the human immunodeficiency virus [11], which demonstrate the versatility and potential applications of Ad vectors in vaccine research and development.
However, pre-existing anti-Ad5 immunity is considered to be the biggest obstacle that candidate Ad5-vectored vaccines must overcome. Studies indicate that the seroprevalence of Ad5 in healthy populations in China is approximately 60% to 82% [12,13,14], while in some sub-Saharan African countries, it may be as high as 100% [15]. When the Ad5 vector vaccine is administered, these pre-existing antibodies can neutralize the vector virus, preventing it from infecting cells and limiting the expression of the antigen gene it carries [16]. This neutralization weakens the level of the specific immune response induced by the vaccine and accelerates the decline of antibody titers, ultimately affecting the vaccine’s immunogenicity.
Despite the widespread pre-existing immunity in humans, Ad5 is still widely regarded as one of the most typical vector systems. During the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, CanSino Biologics Inc. and the Beijing Institute of Biotechnology developed a replication-defective recombinant Ad5 vaccine (Ad5-nCoV) utilizing an E1/E3 deleted, replication-defective Ad5 encoding the full-length, mammalian-expression-optimized Spike gene with a tissue plasminogen activator (tPA) signal peptide [16]. Here, we conduct a pooled analysis of eight clinical trials to assess the impact of pre-existing Ad5 neutralizing antibodies (NAbs) on live SARS-CoV-2 neutralizing antibodies (NAbs) after receiving Ad5-nCoV as either the primary series vaccination or as part of a heterologous prime-boost regimen.

2. Methods

2.1. Study Design and Data Source

We conducted this pooled analysis based on eight completed clinical trials involving Ad5-nCoV (Table S1), such trials being primarily divided into two categories. The first category encompassed three primary immunization trials that involved a single intramuscular injection of Ad5-nCoV containing 3.0 × 1010, 5.0 × 1010, 1.0 × 1011, or 1.5 × 1011 viral particles in healthy individuals aged 6 years and older. The second category comprised five heterologous prime-boost immunization trials. In these trials, aerosolized Ad5-nCoV containing 1.0 × 1010 viral particles or intramuscular Ad5-nCoV containing 3.0 × 1010 viral particles was administered as a third dose to healthy children and adolescents aged 6 to 17 years who had previously received two doses of an inactivated COVID-19 vaccine as their primary immunization. Additionally, aerosolized Ad5-nCoV containing either 1.0 × 1010 or 2.0 × 1010 viral particles, or intramuscular Ad5-nCoV containing 5.0 × 1010 viral particles, was administered as a second, third, or fourth dose to healthy adults aged 18 years or older who had completed one, two, or three doses of vaccination with an inactivated COVID-19 vaccine. We collected and analyzed data primarily including participants’ age, sex, dosage received, pre-existing Ad5 neutralizing antibody (NAb) titers on day 0 pre-vaccination, as well as live SARS-CoV-2 NAb titers both on day 0 pre-vaccination and on day 28 post-vaccination. The specific design and assay protocols of each clinical trial have been fully described in previous publications [17,18,19,20,21].

2.2. Antibody Detection

In all participants included in the eight clinical trials, the detection of pre-existing Ad5 NAbs on day 0 pre-vaccination was based on the firefly luciferase assay system. Serum samples from 3512 participants were subjected to three-fold serial dilutions, ranging from 1:12 to 1:8748, and duplicate sets were prepared for each dilution concentration. To establish a baseline for comparison, a diluent that contained no serum was utilized as a negative control in this experimental setup. In the wells designated for the positive control, serum was excluded entirely, leading to the highest level of luciferase activity observed. This maximum activity was crucial for the precise calculation of 90% neutralization values. Ad5-luciferase was mixed with an equal volume of each diluted serum sample and incubated for 1 h in a 96-well plate, allowing for sufficient interaction [22]. Following this incubation period, a suspension of A549 cells, obtained from the American Strain Preservation Center, was introduced to the mixture. After a 24 h incubation period at 37 °C, the cells underwent a washing procedure, and then they were lysed to facilitate the measurement of luciferase activity. The luciferase measurements were carried out using the Firefly Luciferase Assay system produced by Promega, and the resulting values were quantified utilizing the GloMax Microplate luminometer, also from Promega.
In addition, the levels of live SARS-CoV-2 NAbs against the wild-type strain in the serum samples from all participants were determined on day 0 pre-vaccination and on day 28 post-vaccination with Ad5-nCoV utilizing a microneutralization assay based on cytopathic effects. This involved preparing serum dilutions which were subsequently combined with an equal volume of viral solution, yielding a final viral concentration of 100 TCID50 per well. The titers of the NAbs were expressed as the reciprocal values of the highest serum dilutions that succeeded in protecting at least 50% of cultured cells from observable cytopathic effects caused by the virus. The dilution series for the microneutralization assay commenced at a ratio of either 1:4 or 1:8, ensuring a methodical approach to accurately assess the serum’s neutralizing capabilities against the wild-type strain.

2.3. Statistical Analysis

We selected the per-protocol set (PPS) of participants from these eight clinical trials, totaling 3512 participants, all of whom were vaccinated with Ad5-nCoV. The primary outcome indicator of the study was the geometric mean titer (GMT) of live SARS-CoV-2 NAbs against the wild-type strain on day 28 post-vaccination. In this study, participants were initially divided into two primary age-based cohorts: adolescents aged 6 to 17 and adults aged 18 and older. Within each cohort, individuals were further categorized into three distinct subgroups based on their Ad5-nCoV vaccination schedules: the first subgroup received a single dose via intramuscular injection as the primary regimen (Ad5-IM-prime), the second subgroup received a single dose via intramuscular injection as the heterologous prime-boost regimen (Ad5-IM-boost), and the third subgroup received a single dose via aerosolized inhalation as the heterologous prime-boost regimen (Ad5-IH-boost). It is noteworthy that participants in the Ad5-IM-boost and Ad5-IH-boost subgroups had previously been primed with one or two doses of the inactivated COVID-19 vaccine or had completed homologous booster immunization with three doses of the inactivated COVID-19 vaccine prior to receiving Ad5-nCoV as a heterologous booster. Data from these trials were meticulously categorized and merged according to the age of the participants, the immunization schedule, and the dosage of the vaccination (Table 1).
Data analysis in this study included the following steps. First, stratified analyses of the immune responses were conducted based on pre-existing Ad5 NAb titers on day 0 before vaccination, categorizing participants as negative (less than 1:12), low (1:12 to 1:200), moderate (1:200 to 1:1000), or high (greater than 1:1000). Second, we constructed multiple linear regression models utilizing data from eight clinical trials. In each model, the independent variable was consistently the level of pre-existing Ad5 NAbs, while the dependent variable was the level of live SARS-CoV-2 NAbs on day 28 post-vaccination. We also considered covariates such as age, sex, different immunization schedules or doses, live SARS-CoV-2 NAbs on day 0 pre-vaccination, and the time since the last dose of the inactivated COVID-19 vaccine to assess their impact on the models. In model 1, pre-existing Ad5 NAb titers were treated as categorical variables, while in model 2, they were analyzed as continuous variables. Third, we compared the geometric mean titers (GMTs), geometric mean fold increase (GMFI), and the four-fold increase in titers on day 28 post-vaccination among the three subgroups within both adolescent and adult cohorts.
Continuous data are presented either as the mean with SD or as the median with IQR, while categorical data are presented as percentages. The titers of antibodies were transformed using a logarithmic scale prior to conducting any statistical analyses and are reported as geometric mean titers (GMTs). Categorical data were analyzed using either the chi-squared (χ2) test or Fisher’s exact test. Additionally, analysis of variance (ANOVA) was employed to evaluate the log-transformed antibody titers among the three subgroups with different vaccination regimens, and the Student–Newman–Keuls test was performed to conduct multiple comparisons. All analyses were performed in R version 4.3.3, and figures were created with GraphPad Prism version 9.00 (GraphPad Software, San Diego, CA, USA). Two-sided p values < 0.05 were considered to be significant.

3. Results

3.1. Study Population

This pooled data analysis from eight clinical trials included a total of 3512 participants, who were further categorized into 1273 adolescents aged 6 to 17 years and 2239 adults aged 18 years and older. In the adolescent cohort, participants were divided into three different immunization regimen subgroups: Ad5-IM-prime subgroup (n = 1001), Ad5-IM-boost subgroup (n = 65), and Ad5-IH-boost subgroup (n = 207). Pre-existing Ad5 NAb titers observed on day 0 prior to vaccination showed no statistical difference (p = 0.3146) among the three subgroups, with geometric mean titers (GMTs) of 118.3 (95% CI: 101.7, 137.6) in the Ad5-IM-prime subgroup, 73.0 (95% CI: 37.1, 143.7) in the Ad5-IM-boost subgroup, and 116.4 (95% CI: 81.5, 166.0) in the Ad5-IH-boost subgroup. However, the distribution of pre-existing Ad5 NAb titers among the three subgroups (Ad5-IM-prime, Ad5-IM-boost, and Ad5-IH-boost) showed significant differences (p = 0.0008). In the Ad5-IM-prime subgroup, the proportions of negative (less than 1:12), low (1:12 to 1:200), moderate (1:200 to 1:1000), and high (greater than 1:1000) pre-existing Ad5 NAb titers were 33.6%, 11.4%, 42.4%, and 12.6%, respectively. In the Ad5-IM-boost subgroup, the proportions were 49.2%, 10.8%, 20.0%, and 20.0%, respectively. Meanwhile, the Ad5-IH-boost subgroup exhibited proportions of 36.7%, 10.1%, 33.3%, and 19.8%, respectively.
In the adult cohort, participants were also divided into three different immunization regimen subgroups: Ad5-IM-prime subgroup (n = 1450), Ad5-IM-boost subgroup (n = 396), and Ad5-IH-boost subgroup (n = 393). Pre-existing Ad5 NAb titers observed on day 0 prior to vaccination showed a statistical difference (p = 0.0004) among the three subgroups. GMTs of NAbs against wild-type SARS-CoV-2 were higher in the Ad5-IH-boost subgroup [236.8 (95% CI:189.9, 295.1)] compared to the Ad5-IM-prime subgroup [146.5 (95% CI: 131.5, 163.3)] and the Ad5-IM-boost subgroup [165.7 (95% CI: 134.8, 203.8)]. Specifically, the distribution of pre-existing Ad5 NAb titers among the three subgroups (Ad5-IM-prime, Ad5-IM-boost, and Ad5-IH-boost) showed a significant difference (p = 0.0026). In the Ad5-IM-prime subgroup, the proportions of negative (less than 1:12), low (1:12 to 1:200), moderate (1:200 to 1:1000), and high (greater than 1:1000) pre-existing Ad5 NAb titers were 20.5%, 25.1%, 40.9%, and 13.8%, respectively. In the Ad5-IM-boost subgroup, the proportions were 16.7%, 27.5%, 44.2%, and 11.6%, respectively. Meanwhile, the Ad5-IH-boost subgroup exhibited proportions of 15.0%, 23.9%, 40.7%, and 20.4%, respectively. Other demographic characteristics are reported in Table 2.

3.2. Impact of Pre-Existing Ad5 NAbs on Live SARS-CoV-2 NAbs After Receiving Ad5-nCoV as a Primary Immunization Strategy

In both the adolescent cohort (ages 6–17 years) and the adult cohort (ages 18 years and older), neutralizing antibody titers against wild-type SARS-CoV-2 in the Ad5-IM-prime subgroup were moderate on day 28 post-vaccination. Specifically, the two cohorts exhibited GMTs of 18.5 (95% CI: 17.3, 19.9) for adolescents and 13.9 (95% CI: 13.1, 14.7) for adults, with GMFIs of 9.3 (8.6, 9.9) and 5.5 (5.2, 5.9), respectively. The seroconversion rates were 86.2% for adolescents and 67.4% for adults (Table S2). Based on a stratified analysis of the Ad5-IM-prime subgroup population, serum NAb titers against the wild-type isolate on day 28 post-vaccination showed a gradual decline in the adolescent cohort as pre-existing NAb titers increased, with GMTs of 36.5 (95% CI: 33.0, 40.4), 25.4 (95% CI: 21.9, 29.4), 12.0 (95% CI: 10.9, 13.2), and 9.9 (95% CI: 8.3, 11.9) for negative (less than 1:12), low (1:12 to 1:200), moderate (1:200 to 1:1000), and high (greater than 1:1000) pre-existing NAb titers, respectively. A similar trend was observed in the adult cohort, with GMTs of 35.6 (95% CI: 32.0, 39.7), 14.1 (95% CI: 12.6, 15.6), 9.4 (95% CI: 8.6, 10.2), and 10.7 (95% CI: 9.1, 12.6) for negative (less than 1:12), low (1:12 to 1:200), moderate (1:200 to 1:1000), and high (greater than 1:1000) pre-existing NAb titers, respectively (Figure 1).
Multiple linear regression analyses were conducted on the Ad5-IM-prime subgroup in the adolescent cohort (Table S3). In model 1, when using negative pre-existing NAb titers as the reference, the regression coefficients for the impact of low, moderate, and high pre-existing NAb titers on live SARS-CoV-2 NAb titers post-vaccination were −1.4 (p = 0.0009), −2.9 (p < 0.0001), and −3.5 (p < 0.0001), respectively. This indicates that higher levels of pre-existing Ad5 NAbs have a greater negative impact on live SARS-CoV-2 NAb levels on day 28 post-vaccination. In model 2, the results indicate that the regression coefficient for pre-existing Ad5 NAbs was −1.6 (p < 0.0001), implying a decrease of 1.6 units in post-vaccination antibody levels for each unit increase in pre-existing Ad5 NAbs. Additionally, the effects of the age and sex variables on post-vaccination antibody levels were found to be negative, with estimated values of −1.0 (p < 0.0001) for age and −1.1 (p = 0.0350) for sex, with male sex serving as the reference in model 2.
In line with the findings from the adolescent cohort, the multiple linear regression analyses of the Ad5-IM-prime subgroup in the adult cohort reveal that, whether in model 1 or model 2, higher pre-existing Ad5 NAb titers were associated with a more pronounced negative effect on post-vaccination live SARS-CoV-2 NAb levels (Table S3). In model 1, when using the negative pre-existing NAb titers as the reference, the regression coefficients for the impact of low, moderate, and high pre-existing NAb titers on live SARS-CoV-2 NAb titers post-vaccination were −2.1 (p < 0.0001), −3.4 (p < 0.0001), and −3.5 (p < 0.0001), respectively. Simultaneously, in model 2, when pre-existing NAb titers were treated as a continuous variable, the regression coefficient was −1.7 (p < 0.0001). This finding indicates that, for each unit increase in pre-existing Ad5 NAbs, there is a corresponding decrease of 1.7 units in post-vaccination antibody levels. Compared to the high dosage (1.5 × 1011 vp) in model 2, the regression coefficients for the medium dosage (1.0 × 1011 vp) and low dosage (5.0 × 1010 vp) were −1.6 (p = 0.0104) and −2.2 (p < 0.0001), respectively. Furthermore, the results from model 2 (estimate= −1.0, p < 0.0001) show that age negatively affected live SARS-CoV-2 NAbs on day 28 post-vaccination, consistent with the adolescent cohort, while sex had no significant impact on live SARS-CoV-2 NAbs on day 28, a finding which is inconsistent with the adolescent cohort.

3.3. Impact of Pre-Existing Ad5 NAbs on Live SARS-CoV-2 NAbs After Receiving Ad5-nCoV as a Heterologous Boosting Immunization Strategy

Participants who received heterologous booster vaccinations of Ad5-nCoV administered via either intramuscular injection or aerosolized inhalation experienced a rapid increase in their antibody titers. In the adolescent cohort, 28 days after booster vaccination, the GMTs of NAbs against wild-type SARS-CoV-2 were 349.3 (95% CI: 290.8, 419.5) for the Ad5-IM-boost subgroup and 461.1 (95% CI: 400.9, 530.3) for the Ad5-IH-boost subgroup, with GMFIs of 83.5 (95% CI: 69.7, 100.1) and 102.8 (95% CI: 88.9, 118.8), respectively, showing no statistically significant differences between the two subgroups (Table S2). However, the serum GMTs of NAbs against wild-type SARS-CoV-2 on day 28 post-vaccination in the adult cohort were significantly higher in the Ad5-IH-boost subgroup 1102.7 (95% CI: 982.6, 1237.5) compared with the Ad5-IM-boost subgroup [194.5 (95% CI: 172.0, 219.9), p < 0.0001]. The GMFIs of NAbs against wild-type SARS-CoV-2 increased to 210.8 (95% CI: 180.0, 246.9) in the Ad5-IH-boost subgroup compared with 52.2 (95% CI: 46.4, 58.8) in the Ad5-IM-boost subgroup at the same timepoint (p < 0.0001). In both the adolescent and adult cohorts, the seroconversion rates in the two heterologous sequential booster groups (Ad5-IM-boost and Ad5-IH-boost subgroups) exceeded 98%. Furthermore, similar to the findings in the Ad5-IM-prime subgroup, high levels of baseline pre-existing Ad5 NAb titers were found to reduce the peak of post-vaccination live SARS-CoV-2 NAbs in both the Ad5-IM-boost and Ad5-IH-boost subgroups. Specifically, in the Ad5-IH-boost subgroup of the adult cohort, GMTs of NAbs against wild-type SARS-CoV-2 on day 28 post-vaccination were 2414.1 (95% CI: 2006.9, 2904.0), 1458.9 (95% CI: 1182.5, 1799.8), 842.5 (95% CI: 695.4, 1020.8), and 762.7 (95% CI: 596.2, 975.8) for participants with negative (less than 1:12), low (1:12 to 1:200), moderate (1:200 to 1:1000), and high (greater than 1:1000) pre-existing NAb titers, respectively (Figure 1).
Multiple linear regression analyses were conducted on the Ad5-IM-boost subgroup and Ad5-IH-boost subgroup in the adolescent cohort (Table S4). In model 1 and model 2, the impact of age, sex, and live SARS-CoV-2 NAbs on day 0 pre-vaccination and time since the last dose of inactivated vaccine on post-vaccination antibody levels in the sequential booster subgroup was not statistically significant (p > 0.05). Consistent with the analysis from the Ad5-IM-prime subgroup, the higher the pre-existing Ad5 NAb titers, the greater the impact on post-vaccination antibody levels in model 1. Specifically, using negative pre-existing Ad5 NAb titers as a reference, the regression coefficients for low, moderate, and high pre-existing Ad5 NAb titers were −1.5 (p = 0.0168), −2.0 (p < 0.0001), and −3.2 (p < 0.0001), respectively. Simultaneously, in model 2, when pre-existing NAb titers were treated as a continuous variable, the regression coefficient was −1.5 (p < 0.0001). In model 2, compared to the Ad5-IM-boost subgroup, the live SARS-CoV-2 NAb levels of the Ad5-IH-boost subgroup increased by 1.4 units post-vaccination.
Simultaneously, multiple linear regression analyses were conducted on the Ad5-IM-boost subgroup and Ad5-IH-boost subgroup in the adult cohort (Table S4). In model 1, the Ad5-IH-boost subgroup was observed to exhibit significantly elevated NAb levels post-vaccination, with an estimate of 3.9, when compared to the Ad5-IM-boost subgroup. Furthermore, when examining the influence of pre-existing Ad5 NAb titers, a discernible trend emerged: individuals with low titers showed a negative effect (estimate = −1.7), while those with moderate (estimate = −2.4) and high titers (estimate = −3.0) demonstrated an increasingly pronounced negative impact, using negative pre-existing Ad5 NAb titers as the reference for comparison. In model 2, when pre-existing NAb titers were treated as a continuous variable, the regression coefficient was −1.4 (p < 0.0001). This finding indicates that, for each unit increase in pre-existing Ad5 NAbs, there is a corresponding decrease of 1.4 units in log-transformed post-vaccination antibody levels. Additionally, the impacts of age (estimate = −1.0, p < 0.0001) and time since the last dose of inactivated vaccine (estimate = 1.0, p < 0.0001) on post-vaccination antibody levels in the sequential booster subgroup were found to be statistically significant in model 2.

4. Discussion

Our results show that the Ad5-nCoV vaccine indicates significant NAb titers against live SARS-CoV-2 on day 28 post-vaccination, but a negative correlation with the pre-existing Ad5 NAb titers before vaccination, regardless of whether the cohort is composed of adolescents aged 6 to 17 years or adults aged 18 years and older. Specifically, higher pre-existing Ad5 NAb titers have a greater impact on live SARS-CoV-2 NAbs against the wild-type strain on day 28 post-vaccination, in line with previous reports [16,23,24]. A study has reported that the overall proportion of seropositive healthy adults in China is 72%, with geographical differences and climate identified as the primary factors influencing the levels of Ad5 titers among healthy adults [13]. In our study, among the 1273 children and adolescents assessed, the seropositivity rate for Ad5 NAbs was 65%, while the seropositivity rate for Ad5 NAbs among the 2239 adults evaluated was 80%. These findings are consistent with previous reports [12,14,15]. Human adenovirus type 5 is widely prevalent in the population, resulting in a majority of individuals possessing pre-existing immunity against Ad5.
Overall, our analyses found that booster vaccinations significantly enhanced the serum neutralizing antibody response against SARS-CoV-2 in adults and adolescents who had previously received one, two, or three doses of an inactivated COVID-19 vaccine, with heterologous booster immunization using aerosolized Ad5-nCoV demonstrating particularly strong immunogenicity and much higher serum neutralizing antibody responses. In the adolescent cohort, after adjusting for factors such as pre-existing Ad5 NAb titers, age, sex, the time since the last dose of the inactivated COVID-19 vaccine, and live SARS-CoV-2 NAbs on day 0 pre-vaccination, the results of the multiple regression analysis indicated that the Ad5-IH-boost subgroup had an average increase of 1.4 units in the level of live SARS-CoV-2 NAbs on day 28 post-vaccination compared to the Ad5-IM-boost subgroup. In the adult cohort, the regression analysis results showed that the Ad5-IH-boost subgroup had an average increase of 3.9 units in the level of live SARS-CoV-2 NAbs on day 28 post-vaccination compared to the Ad5-IM-boost subgroup. In the Ad5-IM-prime subgroup, age consistently had a negative impact on NAb titers against live SARS-CoV-2 post-vaccination, regardless of whether the individuals were aged 6–17 or 18 and above. However, when a heterologous booster immunization strategy was implemented, specifically in individuals within the Ad5-IM-boost subgroup and Ad5-IH-boost subgroup, age no longer had a significant impact on antibody levels post-vaccination.
Due to prior natural infection or vaccination, individuals typically possess a pre-existing immune response to the Ad5 vector. These pre-existing Ad5 NAbs may diminish the specific immune responses to vaccination, particularly the humoral immune responses, by neutralizing the viral vector and impacting the efficiency of vaccine particle entry into cells. Prior research has indicated that both heterologous and homologous prime-boost strategies employing Ad5-vectored vaccines are capable of inducing more robust and long-lasting immunogenic responses in populations with elevated pre-existing immunity to the Ad5 vector [9,25,26]. Nevertheless, for homologous prime-boost regimens, it is crucial to note that pre-existing Ad5 NAbs may diminish the vaccine’s immunogenicity. To mitigate the negative effects of these pre-existing Ad5 NAbs, it is recommended to adopt a longer prime-boost interval. Furthermore, a study has demonstrated that the ChAdOx1 nCoV-19 vaccine offers significantly improved protective efficacy when administered with a longer prime-boost interval (≥12 weeks) compared to a shorter interval (<6 weeks) [27].
A study found that administering the AdHu5Ag85A vaccine via intramuscular injection increases the titers of pre-existing Ad5 NAbs in circulation, whereas vaccination through aerosolized inhalation does not enhance the titers of pre-existing Ad5 NAbs in either the airways or circulation [28]. Delivering Ad-vectored vaccines via the respiratory mucosal route in humans can help bypass pre-existing anti-vector immunity, which tends to be more prevalent in circulation than in the lungs31. Furthermore, some studies have shown that respiratory mucosal immunity is more effective than intramuscular immunity in inducing neutralizing antibodies, mucosal tissue-resident memory T cells, and trained airway macrophages [29,30,31,32]. Although oral aerosolized Ad5-nCoV can significantly enhance immunogenicity using a heterologous prime-boost regime, our study still shows in the stratified analysis of pre-existing Ad5 NAb levels that high pre-existing immunity has an inhibitory effect on the levels of live SARS-CoV-2 NAbs post-vaccination.
There are several limitations to our study. First of all, we did not evaluate the antibody levels against other SARS-CoV-2 variants. Second, we did not report the elicited mucosal immunities in individuals who received aerosolized Ad5-nCoV. Third, the sample size of the Ad5-IM-boost subgroup and the Ad5-IH-boost subgroup was relatively small. The relationship between the different routes of Ad5-nCoV administration and the pre-existing Ad5 NAbs titers indeed requires more data to be further clarified. Fourth, in this study, we only evaluated the effect of pre-existing Ad5 NAb on SARS-CoV-2 NAb levels after immunization, but the more complicated pre-existing Ad5 immunity on vaccine-induced T-cell responses was not clear.

5. Conclusions

In conclusion, regardless of whether Ad5-nCoV is administered as a primary vaccination regimen or as a heterologous prime-boost strategy, a negative impact on immunogenicity can still be observed in the presence of high pre-existing immunity. However, when primary immunization is achieved with inactivated vaccines, aerosol inhalation can significantly enhance the immunogenicity of Ad5-nCoV compared to intramuscular injection of Ad5-nCoV as a booster.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/vaccines13030333/s1, Table S1: Clinical trials included in this pooled analysis; Table S2: Neutralizing antibodies against live SARS-CoV-2 on day 28 post-vaccination in the adolescent cohort (ages 6–17 years) and the adult cohort (ages 18 years and older); Table S3: Multivariate linear regression analysis of the participants receiving one shot of Ad5-nCoV by intramuscular injection as a primary immunization strategy; Table S4: Multivariate linear regression analysis of the participants receiving one shot of Ad5-nCoV by intramuscular injection or aerosolized inhalation as a heterologous sequential boosting immunization strategy.

Author Contributions

Conceptualization, J.L. and T.Z.; methodology, J.L. and T.Z.; formal analysis, W.L., Y.L. and R.Q.; investigation, X.L. and F.W.; resources, X.L. and F.W.; data curation, W.L. and Y.L.; writing—original draft preparation, W.L.; writing—review and editing, J.L. and T.Z.; supervision, J.L. and T.Z.; funding acquisition, J.L. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by the National Natural Science Foundation of China (grant numbers 82341031, 82173584, and 82222062), the Major Research Plan of the National Natural Science Foundation of China (grant number 92269205), the Science Fund for Distinguished Young Scholars of Jiangsu Province (grant number BK20220064), and the Jiangsu Provincial Key Project of Science and Technology Plan (grant numbers BE2021738 and BE2023601).

Institutional Review Board Statement

This study conducted a secondary analysis of de-identified data from all participants in the eight included clinical trials, thereby obtaining an ethical exemption. All eight clinical trials were conducted in accordance with the principles of the Declaration of Helsinki and were approved by the Ethics Committee of the Jiangsu Provincial Center for Disease Control and Prevention (approval codes and dates: JSJK2020-A010-01 on 16 March 2020, JSJK2020-A09-01 on 8 April 2020, JSJK2021-A010-01 on 8 May 2021, JSJK2021-A007-01 on 8 May 2021, JSJK2021-A0008-01 on 8 May 2021, JSJK2022-A006-01 on 21 March 2022, JSJK2021-A024-02 on 10 August 2021) and by the Ethics Committee of the Hunan Provincial Center for Disease Control and Prevention (approval code and date: IRB-PJ2022017 on 4 April 2022).

Informed Consent Statement

Informed consent was obtained from all subjects involved in the study.

Data Availability Statement

The data presented in this study are available upon request from the corresponding author.

Acknowledgments

We extend our gratitude to CanSino Biologics for providing all the data for this pooled analysis of the eight clinical trials.

Conflicts of Interest

T.Z., X.L. and F.W. are employees of CanSino Biologics. All the other authors declare no conflicts of interest.

References

  1. Russell, W.C. Adenoviruses: Update on structure and function. J. Gen. Virol. 2009, 90, 1–20. [Google Scholar] [CrossRef]
  2. Tatsis, N.; Ertl, H.C. Adenoviruses as vaccine vectors. Mol. Ther. 2004, 10, 616–629. [Google Scholar] [CrossRef] [PubMed]
  3. Bangari, D.S.; Mittal, S.K. Development of nonhuman adenoviruses as vaccine vectors. Vaccine 2006, 24, 849–862. [Google Scholar] [CrossRef] [PubMed]
  4. Feng, Y.; Li, C.; Hu, P.; Wang, Q.; Zheng, X.; Zhao, Y.; Shi, Y.; Yang, S.; Yi, C.; Feng, Y.; et al. An adenovirus serotype 2-vectored ebolavirus vaccine generates robust antibody and cell-mediated immune responses in mice and rhesus macaques. Emerg. Microbes Infect. 2018, 7, 101. [Google Scholar] [CrossRef]
  5. Tiemessen, M.M.; Solforosi, L.; Dekking, L.; Czapska-Casey, D.; Serroyen, J.; Sullivan, N.J.; Volkmann, A.; Pau, M.G.; Callendret, B.; Schuitemaker, H.; et al. Protection against Marburg Virus and Sudan Virus in NHP by an Adenovector-Based Trivalent Vaccine Regimen Is Correlated to Humoral Immune Response Levels. Vaccines 2022, 10, 1263. [Google Scholar] [CrossRef] [PubMed]
  6. Sullivan, N.J.; Sanchez, A.; Rollin, P.E.; Yang, Z.Y.; Nabel, G.J. Development of a preventive vaccine for Ebola virus infection in primates. Nature 2000, 408, 605–609. [Google Scholar] [CrossRef]
  7. Afrough, S.; Rhodes, S.; Evans, T.; White, R.; Benest, J. Immunologic Dose-Response to Adenovirus-Vectored Vaccines in Animals and Humans: A Systematic Review of Dose-Response Studies of Replication Incompetent Adenoviral Vaccine Vectors when Given via an Intramuscular or Subcutaneous Route. Vaccines 2020, 8, 131. [Google Scholar] [CrossRef]
  8. Zhu, F.C.; Wurie, A.H.; Hou, L.H.; Liang, Q.; Li, Y.H.; Russell, J.B.; Wu, S.P.; Li, J.X.; Hu, Y.M.; Guo, Q.; et al. Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: A single-centre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet 2017, 389, 621–628. [Google Scholar] [CrossRef]
  9. Dolzhikova, I.V.; Zubkova, O.V.; Tukhvatulin, A.I.; Dzharullaeva, A.S.; Tukhvatulina, N.M.; Shcheblyakov, D.V.; Shmarov, M.M.; Tokarskaya, E.A.; Simakova, Y.V.; Egorova, D.A.; et al. Safety and immunogenicity of GamEvac-Combi, a heterologous VSV- and Ad5-vectored Ebola vaccine: An open phase I/II trial in healthy adults in Russia. Hum. Vaccines Immunother. 2017, 13, 613–620. [Google Scholar] [CrossRef]
  10. Guo, Q.; Chan, J.F.; Poon, V.K.; Wu, S.; Chan, C.C.; Hou, L.; Yip, C.C.; Ren, C.; Cai, J.P.; Zhao, M.; et al. Immunization With a Novel Human Type 5 Adenovirus-Vectored Vaccine Expressing the Premembrane and Envelope Proteins of Zika Virus Provides Consistent and Sterilizing Protection in Multiple Immunocompetent and Immunocompromised Animal Models. J. Infect. Dis. 2018, 218, 365–377. [Google Scholar] [CrossRef]
  11. Baden, L.R.; Stieh, D.J.; Sarnecki, M.; Walsh, S.R.; Tomaras, G.D.; Kublin, J.G.; McElrath, M.J.; Alter, G.; Ferrari, G.; Montefiori, D.; et al. Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): A randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study. Lancet HIV 2020, 7, e688–e698. [Google Scholar] [CrossRef] [PubMed]
  12. Yang, W.X.; Zou, X.H.; Jiang, S.Y.; Lu, N.N.; Han, M.; Zhao, J.H.; Guo, X.J.; Zhao, S.C.; Lu, Z.Z. Prevalence of serum neutralizing antibodies to adenovirus type 5 (Ad5) and 41 (Ad41) in children is associated with age and sanitary conditions. Vaccine 2016, 34, 5579–5586. [Google Scholar] [CrossRef] [PubMed]
  13. Yu, B.; Zhou, Y.; Wu, H.; Wang, Z.; Zhan, Y.; Feng, X.; Geng, R.; Wu, Y.; Kong, W.; Yu, X. Seroprevalence of neutralizing antibodies to human adenovirus type 5 in healthy adults in China. J. Med. Virol. 2012, 84, 1408–1414. [Google Scholar] [CrossRef] [PubMed]
  14. Zhang, S.; Huang, W.; Zhou, X.; Zhao, Q.; Wang, Q.; Jia, B. Seroprevalence of neutralizing antibodies to human adenoviruses type-5 and type-26 and chimpanzee adenovirus type-68 in healthy Chinese adults. J. Med. Virol. 2013, 85, 1077–1084. [Google Scholar] [CrossRef]
  15. Mennechet, F.J.D.; Paris, O.; Ouoba, A.R.; Salazar Arenas, S.; Sirima, S.B.; Takoudjou Dzomo, G.R.; Diarra, A.; Traore, I.T.; Kania, D.; Eichholz, K.; et al. A review of 65 years of human adenovirus seroprevalence. Expert. Rev. Vaccines 2019, 18, 597–613. [Google Scholar] [CrossRef]
  16. Sakurai, F.; Tachibana, M.; Mizuguchi, H. Adenovirus vector-based vaccine for infectious diseases. Drug Metab. Pharmacokinet. 2022, 42, 100432. [Google Scholar] [CrossRef]
  17. Tang, R.; Zheng, H.; Wang, B.S.; Gou, J.B.; Guo, X.L.; Chen, X.Q.; Chen, Y.; Wu, S.P.; Zhong, J.; Pan, H.X.; et al. Safety and immunogenicity of aerosolised Ad5-nCoV, intramuscular Ad5-nCoV, or inactivated COVID-19 vaccine CoronaVac given as the second booster following three doses of CoronaVac: A multicentre, open-label, phase 4, randomised trial. Lancet Respir. Med. 2023, 11, 613–623. [Google Scholar] [CrossRef]
  18. Wu, Y.F.; Wei, M.W.; Wang, R.J.; Guo, X.L.; Pan, H.X.; Gao, Y.C.; Li, X.L.; Wang, X.; Ma, X.M.; Wan, P.; et al. Immunogenicity consistency and safety with different production scales of recombinant adenovirus type-5 vectored COVID-19 vaccine in healthy adults: A randomized, double-blinded, immunobridging trial. Expert Rev. Vaccines 2023, 22, 662–670. [Google Scholar] [CrossRef]
  19. Jin, P.F.; Guo, X.L.; Gou, J.B.; Hou, L.H.; Song, Z.Z.; Zhu, T.; Pan, H.X.; Zhu, J.H.; Shi, F.J.; Du, P.; et al. Immunogenicity and safety of heterologous immunisation with Ad5-nCOV in healthy adults aged 60 years and older primed with an inactivated SARS-CoV-2 vaccine (CoronaVac): A phase 4, randomised, observer-blind, non-inferiority trial. Lancet Reg. Health West. Pac. 2023, 38, 100829. [Google Scholar] [CrossRef]
  20. Li, J.X.; Wu, S.P.; Guo, X.L.; Tang, R.; Huang, B.Y.; Chen, X.Q.; Chen, Y.; Hou, L.H.; Liu, J.X.; Zhong, J.; et al. Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: A randomised, open-label, single-centre trial. Lancet Respir. Med. 2022, 10, 739–748. [Google Scholar] [CrossRef]
  21. Huang, T.; Zhang, S.; Dai, D.F.; Wang, B.S.; Zhuang, L.; Huang, H.T.; Wang, Z.F.; Zhao, J.S.; Li, Q.P.; Wu, S.P.; et al. Safety and immunogenicity of heterologous boosting with orally aerosolised or intramuscular Ad5-nCoV vaccine and homologous boosting with inactivated vaccines (BBIBP-CorV or CoronaVac) in children and adolescents: A randomised, open-label, parallel-controlled, non-inferiority, single-centre study. Lancet Respir. Med. 2023, 11, 698–708. [Google Scholar] [CrossRef] [PubMed]
  22. Sprangers, M.C.; Lakhai, W.; Koudstaal, W.; Verhoeven, M.; Koel, B.F.; Vogels, R.; Goudsmit, J.; Havenga, M.J.; Kostense, S. Quantifying adenovirus-neutralizing antibodies by luciferase transgene detection: Addressing preexisting immunity to vaccine and gene therapy vectors. J. Clin. Microbiol. 2003, 41, 5046–5052. [Google Scholar] [CrossRef] [PubMed]
  23. Fausther-Bovendo, H.; Kobinger, G.P. Pre-existing immunity against Ad vectors: Humoral, cellular, and innate response, what’s important? Hum. Vaccines Immunother. 2014, 10, 2875–2884. [Google Scholar] [CrossRef] [PubMed]
  24. Das, S.; Singh, J.; Shaman, H.; Singh, B.; Anantharaj, A.; Sharanabasava, P.; Pandey, R.; Lodha, R.; Pandey, A.K.; Medigeshi, G.R. Pre-existing antibody levels negatively correlate with antibody titers after a single dose of BBV152 vaccination. Nat. Commun. 2022, 13, 3451. [Google Scholar] [CrossRef]
  25. Venkatraman, N.; Ndiaye, B.P.; Bowyer, G.; Wade, D.; Sridhar, S.; Wright, D.; Powlson, J.; Ndiaye, I.; Dieye, S.; Thompson, C.; et al. Safety and Immunogenicity of a Heterologous Prime-Boost Ebola Virus Vaccine Regimen in Healthy Adults in the United Kingdom and Senegal. J. Infect. Dis. 2019, 219, 1187–1197. [Google Scholar] [CrossRef]
  26. Shukarev, G.; Callendret, B.; Luhn, K.; Douoguih, M.; EBOVAC1 consortium. A two-dose heterologous prime-boost vaccine regimen eliciting sustained immune responses to Ebola Zaire could support a preventive strategy for future outbreaks. Hum. Vaccines Immunother. 2017, 13, 266–270. [Google Scholar] [CrossRef]
  27. Voysey, M.; Costa Clemens, S.A.; Madhi, S.A.; Weckx, L.Y.; Folegatti, P.M.; Aley, P.K.; Angus, B.; Baillie, V.L.; Barnabas, S.L.; Bhorat, Q.E.; et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: A pooled analysis of four randomised trials. Lancet 2021, 397, 881–891. [Google Scholar] [CrossRef]
  28. Jeyanathan, M.; Fritz, D.K.; Afkhami, S.; Aguirre, E.; Howie, K.J.; Zganiacz, A.; Dvorkin-Gheva, A.; Thompson, M.R.; Silver, R.F.; Cusack, R.P.; et al. Aerosol delivery, but not intramuscular injection, of adenovirus-vectored tuberculosis vaccine induces respiratory-mucosal immunity in humans. JCI Insight 2022, 7, e155655. [Google Scholar] [CrossRef]
  29. Afkhami, S.; D’Agostino, M.R.; Zhang, A.; Stacey, H.D.; Marzok, A.; Kang, A.; Singh, R.; Bavananthasivam, J.; Ye, G.; Luo, X.; et al. Respiratory mucosal delivery of next-generation COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2. Cell 2022, 185, 896–915.e19. [Google Scholar] [CrossRef]
  30. Lavelle, E.C.; Ward, R.W. Mucosal vaccines—Fortifying the frontiers. Nat. Rev. Immunol. 2022, 22, 236–250. [Google Scholar] [CrossRef]
  31. Xu, F.; Wu, S.; Yi, L.; Peng, S.; Wang, F.; Si, W.; Hou, L.; Zhu, T. Safety, mucosal and systemic immunopotency of an aerosolized adenovirus-vectored vaccine against SARS-CoV-2 in rhesus macaques. Emerg. Microbes Infect. 2022, 11, 438–441. [Google Scholar] [CrossRef]
  32. Jeyanathan, V.; Afkhami, S.; D’Agostino, M.R.; Zganiacz, A.; Feng, X.; Miller, M.S.; Jeyanathan, M.; Thompson, M.R.; Xing, Z. Differential Biodistribution of Adenoviral-Vectored Vaccine Following Intranasal and Endotracheal Deliveries Leads to Different Immune Outcomes. Front. Immunol. 2022, 13, 860399. [Google Scholar] [CrossRef]
Vaccines 13 00333 g001
Figure 1. Neutralizing antibodies against live SARS-CoV-2 on day 28 post-vaccination in the adolescent cohort (ages 6–17 years) (a) and adult cohort (ages 18 years and older) (b), with stratified analysis based on pre-existing Ad5 neutralizing antibodies. GMT = geometric mean antibody titer. Error bars indicate 95% CIs.
Figure 1. Neutralizing antibodies against live SARS-CoV-2 on day 28 post-vaccination in the adolescent cohort (ages 6–17 years) (a) and adult cohort (ages 18 years and older) (b), with stratified analysis based on pre-existing Ad5 neutralizing antibodies. GMT = geometric mean antibody titer. Error bars indicate 95% CIs.
Vaccines 13 00333 g001
Table 1. Data classification of neutralizing antibodies against live SARS-CoV-2 on day 28 post-vaccination for all participants in the eight clinical trials.
Table 1. Data classification of neutralizing antibodies against live SARS-CoV-2 on day 28 post-vaccination for all participants in the eight clinical trials.
Immunization Schedule
[Dosage]		6–17 Years a18 Years or Older a
Ad5-IM-primeAd5-IM
[3.0 × 1010 vp]		NCT04916886/
Ad5-IM
[5.0 × 1010 vp]		/NCT04313127
NCT04341389
NCT04916886
Ad5-IM
[1.0 × 1011 vp]		/NCT04313127
NCT04341389
Ad5-IM
[1.5 × 1011 vp]		/NCT04313127
Ad5-IM-boostICV × 2 + Ad5-IM
[3.0 × 1010 vp]		NCT05330871/
ICV × 1 + Ad5-IM
[5.0 × 1010 vp]		/NCT04892459
NCT04952727
ICV × 2 + Ad5-IM
[5.0 × 1010 vp]		/NCT04892459
NCT04952727
ICV × 3 + Ad5-IM
[5.0 × 1010 vp]		/NCT05303584
Ad5-IH-boostICV × 2 + Ad5-IH
[1.0 × 1010 vp]		NCT05330871NCT05043259
ICV × 2 + Ad5-IH
[2.0 × 1010 vp]		/NCT05043259
ICV × 3 + Ad5-IH
[1.0 × 1010 vp]		/NCT05303584
a All trials in this study are registered with ClinicalTrials.gov. The numbers starting with the characters NCT_ indicate the ClinicalTrials.gov identifier. Abbreviation: vp = viral particles; Ad5-IM= administering Ad5-nCoV by intramuscular injection; Ad5-IH= administering Ad5-nCoV by aerosolized inhalation; ICV = administering inactivated COVID-19 vaccine by intramuscular injection.
Table 2. Baseline characteristics of participants in the eight clinical trials of Ad5-nCoV.
Table 2. Baseline characteristics of participants in the eight clinical trials of Ad5-nCoV.
Ad5-IM-PrimeAd5-IM-BoostAd5-IH-Boostp Value
Adolescent cohort, ages 6–17 years (N = 1273)
  Participants, n100165207/
  Median age (IQR)12.0 (10.0, 14.0)13.0 (9.0, 14.0)12.0 (10.0, 14.0)0.6141
  Sex (%)
    Male542 (54.1%)31 (47.7%)103 (49.8%)0.3446
    Female459 (45.9%)34 (52.3%)104 (50.2%)
  Pre-existing Ad5 neutralising antibodies
    Geometric mean titers (95% CI)118.3 (101.7, 137.6)73.0 (37.1, 143.7)116.4 (81.5, 166.0)0.3146
    Participants with titers < 1:12 (%)336 (33.6%)32 (49.2%)76 (36.7%)0.0008
    1:12 ≤ Participants with titers ≤ 1:200 (%)114 (11.4%)7 (10.8%)21 (10.1%)
    1:200 < Participants with titers ≤ 1:1000 (%)425 (42.4%)13 (20.0%)69 (33.3%)
    Participants with titers > 1:1000 (%)126 (12.6%)13 (20.0%)41 (19.8%)
Adult cohort, ages 18 years and older (N = 2239)
  Participants, n1450396393/
  Median age (IQR)42.0 (33.0, 50.0)53.0 (44.0, 65.0)43.0 (35.0, 50.0)<0.0001
  Sex (%)
    Male749 (51.7%)215 (54.3%)171 (43.5%)0.0048
    Female701 (48.3%)181 (45.7%)222 (56.5%)
  Pre-existing Ad5 neutralising antibodies
    Geometric mean titers (95% CI)146.5 (131.5, 163.3)165.7 (134.8, 203.8)236.8 (189.9, 295.1)0.0004
    Participants with titers < 1:12 (%)297 (20.5%)66 (16.7%)59 (15.0%)0.0026
    1:12 ≤ Participants with titers ≤ 1:200 (%)364 (25.1%)109 (27.5%)94 (23.9%)
    1:200 < Participants with titers ≤ 1:1000 (%)593 (40.9%)175 (44.2%)160 (40.7%)
    Participants with titers > 1:1000 (%)200 (13.8%)46 (11.6%)80 (20.4%)
Data are reported as n (%), the median (IQR), or the geometric mean titer (95% CI). The p values are the result of comparisons among the three subgroups.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Liu, W.; Li, Y.; Li, X.; Wang, F.; Qi, R.; Zhu, T.; Li, J. Pooled Analysis of the Effect of Pre-Existing Ad5 Neutralizing Antibodies on the Immunogenicity of Adenovirus Type 5 Vector-Based COVID-19 Vaccine from Eight Clinical Trials. Vaccines 2025, 13, 333. https://doi.org/10.3390/vaccines13030333

AMA Style

Liu W, Li Y, Li X, Wang F, Qi R, Zhu T, Li J. Pooled Analysis of the Effect of Pre-Existing Ad5 Neutralizing Antibodies on the Immunogenicity of Adenovirus Type 5 Vector-Based COVID-19 Vaccine from Eight Clinical Trials. Vaccines. 2025; 13(3):333. https://doi.org/10.3390/vaccines13030333

Chicago/Turabian Style

Liu, Wenqing, Yuqing Li, Xiaolong Li, Feiyu Wang, Runjie Qi, Tao Zhu, and Jingxin Li. 2025. "Pooled Analysis of the Effect of Pre-Existing Ad5 Neutralizing Antibodies on the Immunogenicity of Adenovirus Type 5 Vector-Based COVID-19 Vaccine from Eight Clinical Trials" Vaccines 13, no. 3: 333. https://doi.org/10.3390/vaccines13030333

APA Style

Liu, W., Li, Y., Li, X., Wang, F., Qi, R., Zhu, T., & Li, J. (2025). Pooled Analysis of the Effect of Pre-Existing Ad5 Neutralizing Antibodies on the Immunogenicity of Adenovirus Type 5 Vector-Based COVID-19 Vaccine from Eight Clinical Trials. Vaccines, 13(3), 333. https://doi.org/10.3390/vaccines13030333

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop